{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T05:44:19Z","timestamp":1780638259047,"version":"3.54.1"},"update-to":[{"DOI":"10.1002\/14651858.cd012448","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2019,8,16]],"date-time":"2019-08-16T00:00:00Z","timestamp":1565913600000}}],"reference-count":81,"publisher":"Wiley","issue":"8","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd012448.pub2","type":"journal-article","created":{"date-parts":[[2019,8,19]],"date-time":"2019-08-19T12:47:48Z","timestamp":1566218868000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["TNF-\u03b1 blockers for the treatment of Kawasaki disease in children"],"prefix":"10.1002","volume":"2019","author":[{"given":"Noyuri","family":"Yamaji","sequence":"first","affiliation":[{"name":"St. Luke's International University; Global Health Nursing, Graduate School of Nursing Sciences; 10-1 Akashi-cho Chuo-Ku Tokyo MS Japan 104-0044"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katharina","family":"da Silva Lopes","sequence":"additional","affiliation":[{"name":"St. Luke's International University; Graduate School of Public Health; 3-6-2 Tsukiji Chuo-Ku Tokyo MS Japan 104-0045"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tetsuo","family":"Shoda","sequence":"additional","affiliation":[{"name":"Cincinnati Children's Hospital Medical Center; Division of Allergy & Immunology; 240 Albert Sabin Way Cincinnati USA 45229"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazue","family":"Ishitsuka","sequence":"additional","affiliation":[{"name":"National Center for Child Health and Development; Department of General Paediatrics and Interdisciplinary Medicine; 2-10-1 Okura Setagaya Tokyo Tokyo Japan 157-8535"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tohru","family":"Kobayashi","sequence":"additional","affiliation":[{"name":"National Center for Child Health and Development; Department of Development Strategy; 2-10-1 Okura Setagaya Tokyo Tokyo Japan 157-8535"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erika","family":"Ota","sequence":"additional","affiliation":[{"name":"St. Luke's International University; Global Health Nursing, Graduate School of Nursing Sciences; 10-1 Akashi-cho Chuo-Ku Tokyo MS Japan 104-0044"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rintaro","family":"Mori","sequence":"additional","affiliation":[{"name":"National Center for Child Health and Development; Department of Health Policy; 2-10-1 Okura Setagaya-ku Tokyo Tokyo Japan 157-0074"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2019,8,16]]},"reference":[{"issue":"6","key":"10.1002\/14651858.CD012448.pub2-BIB0001|cit1","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1016\/j.jpeds.2008.06.011","article-title":"Infliximab treatment of intravenous immunoglobulin-resistant Kawasaki disease","volume":"153","author":"Burns","year":"2008","journal-title":"Journal of Pediatrics"},{"issue":"3","key":"10.1002\/14651858.CD012448.pub2-BIB0002|cit2","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1111\/cei.12182","article-title":"Immune-monitoring in Kawasaki disease patients treated with infliximab and intravenous immunoglobulin","volume":"174","author":"Burns","year":"2013","journal-title":"Clinical and Experimental Immunology"},{"key":"10.1002\/14651858.CD012448.pub2-BIB0003|cit3","unstructured":"NCT00271570 Infliximab (Remicade) for patients with acute Kawasaki disease clinicaltrials.gov\/ct2\/show\/NCT00271570"},{"issue":"1","key":"10.1002\/14651858.CD012448.pub2-BIB0004|cit4","doi-asserted-by":"crossref","first-page":"1994","DOI":"10.1038\/s41598-017-18387-7","article-title":"Infliximab versus intravenous immunoglobulin for refractory Kawasaki disease: a phase 3, randomized, open-label, active-controlled, parallel-group, multicenter trial","volume":"8","author":"Mori","year":"2018","journal-title":"Scientific Reports"},{"key":"10.1002\/14651858.CD012448.pub2-BIB0005|cit5","unstructured":"Mori M Hara T Kikuchi M Shimizu H Miyamoto T Iwashima S Infliximab versus intravenous immunoglobulin for refractory Kawasaki disease: a phase 3, randomized, open-label, active-controlled, parallel-group, multicenter trial. Supplementary information Available from https:\/\/static-content.springer.com\/esm\/art%3A10.1038%2Fs41598-017-18387-7\/MediaObjects\/41598_2017_18387_MOESM1_ESM.pdf"},{"key":"10.1002\/14651858.CD012448.pub2-BIB0006|cit6","unstructured":"NCT01596335 Clinical study of TA-650 in patients with refractory Kawasaki disease clinicaltrials.gov\/ct2\/show\/NCT01596335"},{"key":"10.1002\/14651858.CD012448.pub2-BIB0007|cit7","first-page":"A15447","article-title":"Multicenter, randomized, double-blind trial of etanercept in acute Kawasaki disease","volume":"136","author":"Portman","year":"2018","journal-title":"Circulation"},{"key":"10.1002\/14651858.CD012448.pub2-BIB0008|cit8","unstructured":"Portman MA Dahdah N Olson AK A randomized multicenter double-blind placebo controlled trial of etanercept acute Kawasaki Disease Progress and harmony for Kawasaki disease. The 12th International Kawasaki Disease Symposium; 2018 June 12-15; Pacifico Yokohama, Japan 2018 MPS2 11"},{"issue":"3","key":"10.1002\/14651858.CD012448.pub2-BIB0009|cit9","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1016\/j.ahj.2010.12.003","article-title":"Etanercept as adjunctive treatment for acute Kawasaki disease: study design and rationale","volume":"161","author":"Portman","year":"2011","journal-title":"American Heart Journal"},{"issue":"12","key":"10.1002\/14651858.CD012448.pub2-BIB0010|cit10","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1097\/INF.0000000000000891","article-title":"Patterns of fever in children after primary treatment for Kawasaki disease","volume":"34","author":"Jaggi","year":"2015","journal-title":"Pediatric Infectious Disease Journal"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD012448.pub2-BIB0011|cit11","doi-asserted-by":"crossref","first-page":"Abstract O.38","DOI":"10.1161\/circ.131.suppl_2.o38","article-title":"Fever patterns in KD patients after treatment with IVIG","volume":"131","author":"Jaggi","year":"2015","journal-title":"Circulation"},{"key":"10.1002\/14651858.CD012448.pub2-BIB0012|cit12","unstructured":"NCT00760435 Infliximab plus intravenous immunoglobulin for the primary treatment of Kawasaki disease clinicaltrials.gov\/ct2\/show\/NCT00760435"},{"key":"10.1002\/14651858.CD012448.pub2-BIB0013|cit13","first-page":"53","article-title":"TNF\u03b1 blockade in Kawasaki disease: putting out the fire","volume":"54 (Suppl 1)","author":"Tremoulet","year":"2012","journal-title":"Pediatrics International"},{"issue":"9930","key":"10.1002\/14651858.CD012448.pub2-BIB0014|cit14","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1016\/S0140-6736(13)62298-9","article-title":"Infliximab for intensification of primary therapy for Kawasaki disease: a phase 3 randomised, double-blind, placebo-controlled trial","volume":"383","author":"Tremoulet","year":"2014","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD012448.pub2-BIB0015|cit15","unstructured":"Tremoulet AH Jain S Jaggi P Jimenez-Fernandez S Pancheri JM Sun X Infliximab for intensification of primary therapy for Kawasaki disease: a phase 3 randomised, double-blind, placebo-controlled trial. Supplementary appendix Available from https:\/\/www.thelancet.com\/cms\/10.1016\/S0140-6736(13)62298-9\/attachment\/e3c14130-fce0-41a3-b703-0c99b601b4e6\/mmc1.pdf"},{"issue":"4","key":"10.1002\/14651858.CD012448.pub2-BIB0016|cit16","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1097\/INF.0000000000001039","article-title":"Infliximab as the first retreatment in patients with Kawasaki disease resistant to initial intravenous immunoglobulin","volume":"35","author":"Youn","year":"2016","journal-title":"Pediatric Infectious Disease Journal"},{"key":"10.1002\/14651858.CD012448.pub2-BIB0017|cit17","unstructured":"Youn Y Kim J Hong YM Sohn S Infliximab as the first retreatment in patients with Kawasaki disease resistant to initial intravenous immunoglobulin. Supplementary information Available from http:\/\/download.lww.com\/wolterskluwer_vitalstream_com\/PermaLink\/INF\/C\/INF_2015_12_10_SOHN_215-841_SDC1.pdf"},{"key":"10.1002\/14651858.CD012448.pub2-BIB0018|cit18","unstructured":"Youn Y Kim J Hong YM Sohn S Infliximab as the first retreatment in patients with Kawasaki disease resistant to initial intravenous immunoglobulin. Supplementary information Available from https:\/\/download.lww.com\/wolterskluwer_vitalstream_com\/PermaLink\/INF\/C\/INF_2015_12_10_SOHN_215-841_SDC2.pdf"},{"key":"10.1002\/14651858.CD012448.pub2-BIB0019|cit19","unstructured":"ChiCTR-IOR-16007862 Research on individualized treatment for intravenous immunoglobulin resistant children with Kawasaki disease chictr.org.cn\/showprojen.aspx?proj=13290"},{"key":"10.1002\/14651858.CD012448.pub2-BIB0020|cit20","unstructured":"NCT02298062 Infliximab for Kawasaki Disease patients resistant to IVIG: a multicentre, prospective, randomised trial clinicaltrials.gov\/ct2\/show\/NCT02298062"},{"issue":"4","key":"10.1002\/14651858.CD012448.pub2-BIB0021|cit21","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1007\/s40674-016-0053-8","article-title":"TNF and IL-1 targeted treatment in Kawasaki disease","volume":"2","author":"Aeschlimann","year":"2016","journal-title":"Current Treatment Options in Rheumatology"},{"issue":"3","key":"10.1002\/14651858.CD012448.pub2-BIB0022|cit22","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1080\/1744666X.2017.1232165","article-title":"Kawasaki disease: etiopathogenesis and novel treatment strategies","volume":"13","author":"Agarwal","year":"2017","journal-title":"Expert Review of Clinical Immunology"},{"issue":"2","key":"10.1002\/14651858.CD012448.pub2-BIB0023|cit23","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1111\/j.1442-200x.2005.02033.x","article-title":"Kawasaki Disease Research Committee. Revision of diagnostic guidelines for Kawasaki disease (the 5th revised edition)","volume":"47","author":"Ayusawa","year":"2005","journal-title":"Pediatrics International"},{"issue":"4","key":"10.1002\/14651858.CD012448.pub2-BIB0024|cit24","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD004175.pub2","article-title":"Salicylate for the treatment of Kawasaki disease in children","author":"Baumer","year":"2006","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"1","key":"10.1002\/14651858.CD012448.pub2-BIB0025|cit25","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/0735-1097(96)00099-X","article-title":"Sequelae of Kawasaki disease in adolescents and young adults","volume":"28","author":"Burns","year":"1996","journal-title":"Journal of the American College of Cardiology"},{"issue":"12","key":"10.1002\/14651858.CD012448.pub2-BIB0026|cit26","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1097\/00006454-199812000-00009","article-title":"Intravenous gamma-globulin treatment and retreatment in Kawasaki disease. US\/Canadian Kawasaki Syndrome Study Group","volume":"17","author":"Burns","year":"1998","journal-title":"Pediatric Infectious Disease Journal"},{"issue":"5","key":"10.1002\/14651858.CD012448.pub2-BIB0027|cit27","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1016\/j.jpeds.2004.12.022","article-title":"Infliximab treatment for refractory Kawasaki syndrome","volume":"146","author":"Burns","year":"2005","journal-title":"Journal of Pediatrics"},{"issue":"6","key":"10.1002\/14651858.CD012448.pub2-BIB0028|cit28","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1016\/j.jpeds.2010.06.014","article-title":"Prospective open-label trial of etanercept as adjunctive therapy for Kawasaki disease","volume":"157","author":"Choueiter","year":"2010","journal-title":"Journal of Pediatrics"},{"issue":"6","key":"10.1002\/14651858.CD012448.pub2-BIB0029|cit29","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1542\/peds.96.6.1057","article-title":"The prevention of coronary artery aneurysm in Kawasaki disease: a meta-analysis on the efficacy of aspirin and immunoglobulin treatment","volume":"96","author":"Durongpisitkul","year":"1995","journal-title":"Pediatrics"},{"key":"10.1002\/14651858.CD012448.pub2-BIB0030|cit30","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1186\/s12887-015-0424-6","article-title":"Plasma levels of monokine induced by interferon-gamma\/chemokine (C-X-X motif) ligand 9, thymus and activation-regulated chemokine\/chemokine (C-C motif) ligand 17 in children with Kawasaki disease","volume":"15","author":"Feng","year":"2015","journal-title":"BMC Pediatrics"},{"issue":"2","key":"10.1002\/14651858.CD012448.pub2-BIB0031|cit31","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/0014-5793(91)80803-B","article-title":"Tumor necrosis factor. Characterization at the molecular, cellular and in vivo level","volume":"285","author":"Fiers","year":"1991","journal-title":"FEBS Letters"},{"issue":"2","key":"10.1002\/14651858.CD012448.pub2-BIB0032|cit32","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/0090-1229(88)90088-8","article-title":"Peripheral blood monocyte\/macrophages and serum tumor necrosis factor in Kawasaki disease","volume":"48","author":"Furukawa","year":"1988","journal-title":"Clinical Immunology and Immunopathology"},{"issue":"8411","key":"10.1002\/14651858.CD012448.pub2-BIB0033|cit33","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1016\/S0140-6736(84)91504-6","article-title":"High-dose intravenous gammaglobulin for Kawasaki disease","volume":"2","author":"Furusho","year":"1984","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD012448.pub2-BIB0034|cit34","unstructured":"GRADE Working Group, McMaster University GRADEpro GDT 2014"},{"key":"10.1002\/14651858.CD012448.pub2-BIB0035|cit35","unstructured":"Higgins JP Altman DG Sterne JAC editor(s) Chapter 8: Assessing risk of bias in included studies. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from handbook.cochrane.org"},{"key":"10.1002\/14651858.CD012448.pub2-BIB0036|cit36","unstructured":"Sterne JAC Egger M Moher D editor(s) Chapter 10: Addressing reporting biases. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from handbook.cochrane.org"},{"issue":"6","key":"10.1002\/14651858.CD012448.pub2-BIB0037|cit37","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1203\/PDR.0b013e31819ed68d","article-title":"Infliximab reduces the cytokine-mediated inflammation but does not suppress cellular infiltration of the vessel wall in refractory Kawasaki disease","volume":"65","author":"Hirono","year":"2009","journal-title":"Pediatric Research"},{"issue":"3","key":"10.1002\/14651858.CD012448.pub2-BIB0038|cit38","doi-asserted-by":"crossref","first-page":"e401","DOI":"10.1542\/peds.2008-2187","article-title":"Epidemiologic features of Kawasaki disease in Taiwan, 2003-2006","volume":"123","author":"Huang","year":"2009","journal-title":"Pediatrics"},{"issue":"10","key":"10.1002\/14651858.CD012448.pub2-BIB0039|cit39","doi-asserted-by":"crossref","first-page":"6294","DOI":"10.4049\/jimmunol.176.10.6294","article-title":"TNF-alpha is necessary for induction of coronary artery inflammation and aneurysm formation in an animal model of Kawasaki disease","volume":"176","author":"Hui-Yuen","year":"2006","journal-title":"Journal of Immunology"},{"issue":"2","key":"10.1002\/14651858.CD012448.pub2-BIB0040|cit40","doi-asserted-by":"crossref","first-page":"183","DOI":"10.4070\/kcj.2018.0214","article-title":"Infliximab treatment for intravenous immunoglobulin-resistant Kawasaki disease: a multicenter study in Korea","volume":"49","author":"Hur","year":"2019","journal-title":"Korean Circulation Journal"},{"key":"10.1002\/14651858.CD012448.pub2-BIB0041|cit41","first-page":"1166","article-title":"Effectiveness of tocilizumab for intravenous immunoglobulin-resistant Kawasaki disease","volume":"29","author":"Imagawa","year":"2009","journal-title":"Progress in Medicine"},{"issue":"3","key":"10.1002\/14651858.CD012448.pub2-BIB0042|cit42","first-page":"178\u2013222","article-title":"Acute febrile mucocutaneous syndrome with lymphoid involvement with specific desquamation of the fingers and toes in children","volume":"16","author":"Kawasaki","year":"1967","journal-title":"Arerugi"},{"issue":"12","key":"10.1002\/14651858.CD012448.pub2-BIB0043|cit43","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1038\/ng.981","article-title":"Genome-wide association study identifies FCGR2A as a susceptibility locus for Kawasaki disease","volume":"43","author":"Khor","year":"2011","journal-title":"Nature Genetics"},{"issue":"1","key":"10.1002\/14651858.CD012448.pub2-BIB0044|cit44","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1097\/INF.0000000000000010","article-title":"Epidemiologic features of Kawasaki disease in South Korea: data from nationwide survey, 2009-2011","volume":"33","author":"Kim","year":"2014","journal-title":"Pediatric Infectious Disease Journal"},{"issue":"2","key":"10.1002\/14651858.CD012448.pub2-BIB0045|cit45","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/j.jpeds.2013.01.022","article-title":"Efficacy of intravenous immunoglobulin combined with prednisolone following resistance to initial intravenous immunoglobulin treatment of acute Kawasaki disease","volume":"163","author":"Kobayashi","year":"2013","journal-title":"Journal of Pediatrics"},{"issue":"16","key":"10.1002\/14651858.CD012448.pub2-BIB0046|cit46","doi-asserted-by":"crossref","first-page":"1850","DOI":"10.1007\/s00018-005-5022-6","article-title":"The therapeutic potential of tumor necrosis factor for autoimmune disease: a mechanistically based hypothesis","volume":"62","author":"Kodama","year":"2005","journal-title":"Cellular and Molecular Life Sciences"},{"key":"10.1002\/14651858.CD012448.pub2-BIB0047|cit47","unstructured":"Lefebvre C Manheimer E Glanville J Chapter 6: Searching for studies. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from handbook.cochrane.org"},{"issue":"6","key":"10.1002\/14651858.CD012448.pub2-BIB0048|cit48","doi-asserted-by":"crossref","first-page":"1958","DOI":"10.1084\/jem.164.6.1958","article-title":"Two monokines, interleukin 1 and tumor necrosis factor, render cultured vascular endothelial cells susceptible to lysis by antibodies circulating during Kawasaki syndrome","volume":"164","author":"Leung","year":"1986","journal-title":"Journal of Experimental Medicine"},{"issue":"3","key":"10.1002\/14651858.CD012448.pub2-BIB0049|cit49","doi-asserted-by":"crossref","first-page":"239","DOI":"10.2188\/jea.JE20140089","article-title":"Descriptive epidemiology of Kawasaki disease in Japan, 2011-2012: from the results of the 22nd nationwide survey","volume":"25","author":"Makino","year":"2015","journal-title":"Journal of Epidemiology\/Japan Epidemiological Association"},{"issue":"4","key":"10.1002\/14651858.CD012448.pub2-BIB0050|cit50","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1111\/ped.13809","article-title":"Nationwide epidemiologic survey of Kawasaki disease in Japan, 2015-2016","volume":"61","author":"Makino","year":"2019","journal-title":"Pediatrics International"},{"key":"10.1002\/14651858.CD012448.pub2-BIB0051|cit51","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.jpeds.2017.10.013","article-title":"Infliximab for the treatment of refractory Kawasaki disease: a nationwide survey in Japan","volume":"195","author":"Masuda","year":"2018","journal-title":"Journal of Pediatrics"},{"issue":"1","key":"10.1002\/14651858.CD012448.pub2-BIB0052|cit52","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/0090-1229(90)90166-N","article-title":"Serum levels of tumor necrosis factor, interleukin 2 receptor, and interferon-gamma in Kawasaki disease involved coronary-artery lesions","volume":"56","author":"Matsubara","year":"1990","journal-title":"Clinical Immunology and Immunopathology"},{"issue":"17","key":"10.1002\/14651858.CD012448.pub2-BIB0053|cit53","doi-asserted-by":"crossref","first-page":"e927","DOI":"10.1161\/CIR.0000000000000484","article-title":"Diagnosis, Treatment, and Long-Term Management of Kawasaki Disease: A Scientific Statement for Health Professionals From the American Heart Association","volume":"135","author":"McCrindle","year":"2017","journal-title":"Circulation"},{"issue":"4","key":"10.1002\/14651858.CD012448.pub2-BIB0054|cit54","doi-asserted-by":"crossref","first-page":"864","DOI":"10.3899\/jrheum.110877","article-title":"Efficacy and limitation of infliximab treatment for children with Kawasaki disease intractable to intravenous immunoglobulin therapy: report of an open-label case series","volume":"39","author":"Mori","year":"2012","journal-title":"Journal of Rheumatology"},{"issue":"4","key":"10.1002\/14651858.CD012448.pub2-BIB0055|cit55","doi-asserted-by":"crossref","first-page":"167","DOI":"10.2188\/jea.JE2008001","article-title":"Epidemiologic features of Kawasaki disease in Japan: results from the nationwide survey in 2005-2006","volume":"18","author":"Nakamura","year":"2008","journal-title":"Journal of Epidemiology"},{"issue":"4","key":"10.1002\/14651858.CD012448.pub2-BIB0056|cit56","doi-asserted-by":"crossref","first-page":"302","DOI":"10.2188\/jea.JE20090180","article-title":"Epidemiologic features of Kawasaki disease in Japan: results of the 2007-2008 nationwide survey","volume":"20","author":"Nakamura","year":"2010","journal-title":"Journal of Epidemiology"},{"issue":"3","key":"10.1002\/14651858.CD012448.pub2-BIB0057|cit57","doi-asserted-by":"crossref","first-page":"216","DOI":"10.2188\/jea.JE20110126","article-title":"Epidemiologic features of Kawasaki disease in Japan: results of the 2009-2010 nationwide survey","volume":"22","author":"Nakamura","year":"2012","journal-title":"Journal of Epidemiology"},{"issue":"6","key":"10.1002\/14651858.CD012448.pub2-BIB0058|cit58","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1056\/NEJM198608073150601","article-title":"The treatment of Kawasaki syndrome with intravenous gamma globulin","volume":"315","author":"Newburger","year":"1986","journal-title":"New England Journal of Medicine"},{"issue":"17","key":"10.1002\/14651858.CD012448.pub2-BIB0059|cit59","doi-asserted-by":"crossref","first-page":"2747","DOI":"10.1161\/01.CIR.0000145143.19711.78","article-title":"Diagnosis, treatment, and long-term management of Kawasaki disease: a statement for health professionals from the Committee on Rheumatic Fever, Endocarditis and Kawasaki Disease, Council on Cardiovascular Disease in the Young, American Heart Association","volume":"110","author":"Newburger","year":"2004","journal-title":"Circulation"},{"issue":"4","key":"10.1002\/14651858.CD012448.pub2-BIB0060|cit60","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD004000","article-title":"Intravenous immunoglobulin for the treatment of Kawasaki disease in children","author":"Oates-Whitehead","year":"2003","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD012448.pub2-BIB0061|cit61","unstructured":"Ogawa S Ayusawa M Ishii M Ogino H Saji T Nishigaki K Guidlines for diagnosis and management of cardiovascular sequelae in Kawasaki disease (JCS2013) Available from www.j-circ.or.jp\/guideline\/pdf\/JCS2013_ogawas_d.pdf 2013"},{"issue":"3","key":"10.1002\/14651858.CD012448.pub2-BIB0062|cit62","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1038\/pr.2014.92","article-title":"Transcriptional regulation by infliximab therapy in Kawasaki disease patients with immunoglobulin resistance","volume":"76","author":"Ogihara","year":"2014","journal-title":"Pediatric Research"},{"issue":"1","key":"10.1002\/14651858.CD012448.pub2-BIB0063|cit63","doi-asserted-by":"crossref","first-page":"120","DOI":"10.3109\/14397595.2013.854061","article-title":"The role of TNF-\u03b1 in a murine model of Kawasaki disease arteritis induced with a Candida albicans cell wall polysaccharide","volume":"24","author":"Oharaseki","year":"2014","journal-title":"Modern Rheumatology\/the Japan Rheumatism Association"},{"issue":"1","key":"10.1002\/14651858.CD012448.pub2-BIB0064|cit64","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1038\/ng.2007.59","article-title":"ITPKC functional polymorphism associated with Kawasaki disease susceptibility and formation of coronary artery aneurysms","volume":"40","author":"Onouchi","year":"2008","journal-title":"Nature Genetics"},{"issue":"14","key":"10.1002\/14651858.CD012448.pub2-BIB0065|cit65","doi-asserted-by":"crossref","first-page":"2898","DOI":"10.1093\/hmg\/ddq176","article-title":"Common variants in CASP3 confer susceptibility to Kawasaki disease","volume":"19","author":"Onouchi","year":"2010","journal-title":"Human Molecular Genetics"},{"issue":"5","key":"10.1002\/14651858.CD012448.pub2-BIB0066|cit66","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1038\/ng.2220","article-title":"A genome-wide association study identifies three new risk loci for Kawasaki disease","volume":"44","author":"Onouchi","year":"2012","journal-title":"Nature Genetics"},{"issue":"1","key":"10.1002\/14651858.CD012448.pub2-BIB0067|cit67","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1111\/1756-185X.13218","article-title":"The genetics of Kawasaki disease","volume":"21","author":"Onouchi","year":"2018","journal-title":"International Journal of Rheumatic Diseases"},{"key":"10.1002\/14651858.CD012448.pub2-BIB0068|cit68","unstructured":"The Nordic Cochrane Centre, The Cochrane Collaboration Review Manager (RevMan) 2014"},{"issue":"5","key":"10.1002\/14651858.CD012448.pub2-BIB0069|cit69","doi-asserted-by":"crossref","first-page":"875\u20136","DOI":"10.1016\/j.jpeds.2012.01.018","article-title":"Resistant Kawasaki disease treated with anti-CD20","volume":"160","author":"Sauvaget","year":"2012","journal-title":"Journal of Pediatrics"},{"issue":"6","key":"10.1002\/14651858.CD012448.pub2-BIB0070|cit70","first-page":"391\u2013400","article-title":"GRADE: from grading the evidence to developing recommendations. A description of the system and a proposal regarding the transferability of the results of clinical research to clinical practice","volume":"103","author":"Sch\u00fcnemann","year":"2009","journal-title":"Zeitschrift f\u00fcr Evidenz, Fortbildung und Qualit\u00e4t im Gesundheitswesen"},{"key":"10.1002\/14651858.CD012448.pub2-BIB0071|cit71","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/1546-0096-12-26","article-title":"High dose anakinra for treatment of severe neonatal Kawasaki disease: a case report","volume":"12","author":"Shafferman","year":"2014","journal-title":"Pediatric Rheumatology Online Journal"},{"key":"10.1002\/14651858.CD012448.pub2-BIB0072|cit72","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1136\/archdischild-2014-307536","article-title":"The epidemiology of Kawasaki disease: a global update","volume":"100","author":"Singh","year":"2015","journal-title":"Archives of Disease in Childhood"},{"issue":"3 Suppl 97","key":"10.1002\/14651858.CD012448.pub2-BIB0073|cit73","first-page":"S134","article-title":"Infliximab is the new kid on the block in Kawasaki disease: a single-centre study over 8 years from North India","volume":"34","author":"Singh","year":"2016","journal-title":"Clinical and Experimental Rheumatology"},{"issue":"7","key":"10.1002\/14651858.CD012448.pub2-BIB0074|cit74","doi-asserted-by":"crossref","first-page":"334","DOI":"10.4070\/kcj.2010.40.7.334","article-title":"Infliximab treatment for refractory Kawasaki disease in Korean children","volume":"40","author":"Song","year":"2010","journal-title":"Korean Circulation Journal"},{"issue":"6","key":"10.1002\/14651858.CD012448.pub2-BIB0075|cit75","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1016\/S0022-3476(97)70038-6","article-title":"Prevalence of coronary artery abnormalities in Kawasaki disease is highly dependent on gamma globulin dose but independent of salicylate dose","volume":"131","author":"Terai","year":"1997","journal-title":"Journal of Pediatrics"},{"issue":"1","key":"10.1002\/14651858.CD012448.pub2-BIB0076|cit76","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.jpeds.2007.12.021","article-title":"Resistance to intravenous immunoglobulin in children with Kawasaki disease","volume":"153","author":"Tremoulet","year":"2008","journal-title":"Journal of Pediatrics"},{"issue":"2","key":"10.1002\/14651858.CD012448.pub2-BIB0077|cit77","doi-asserted-by":"crossref","first-page":"79","DOI":"10.2188\/jea.JE20110131","article-title":"Epidemiology of Kawasaki disease in Asia, Europe, and the United States","volume":"22","author":"Uehara","year":"2012","journal-title":"Journal of Epidemiology\/Japan Epidemiological Association"},{"issue":"4","key":"10.1002\/14651858.CD012448.pub2-BIB0078|cit78","first-page":"808","article-title":"Infliximab as a novel therapy for refractory Kawasaki disease","volume":"31","author":"Weiss","year":"2004","journal-title":"Journal of Rheumatology"},{"key":"10.1002\/14651858.CD012448.pub2-BIB0079|cit79","volume-title":"Epidemiology of Kawasaki disease: a 30-year achievement","author":"Yanagawa","year":"2004"},{"issue":"4","key":"10.1002\/14651858.CD012448.pub2-BIB0080|cit80","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1111\/j.1442-200X.2006.02221.x","article-title":"Incidence of Kawasaki disease in Japan: the nationwide surveys of 1999-2002","volume":"48","author":"Yanagawa","year":"2006","journal-title":"Pediatrics International"},{"issue":"11","key":"10.1002\/14651858.CD012448.pub2-BIB0081|cit81","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD012448","article-title":"TNF-\u03b1 blockers for the treatment of Kawasaki disease in children","author":"Shoda","year":"2016","journal-title":"Cochrane Database of Systematic Reviews"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cochranelibrary.com\/cdsr\/doi\/10.1002\/14651858.CD012448.pub2\/epdf\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T06:31:30Z","timestamp":1779949890000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD012448.pub2"}},"subtitle":[],"editor":[{"name":"Cochrane Vascular Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2019,8,16]]},"references-count":81,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2019,8]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd012448.pub2","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,8,16]]}}}